Moderna Valuation
Is MRNA * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MRNA * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MRNA * (MX$2150) is trading below our estimate of fair value (MX$3410.59)
Significantly Below Fair Value: MRNA * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MRNA *?
Other financial metrics that can be useful for relative valuation.
What is MRNA *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$49.46b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 7.5x |
Enterprise Value/EBITDA | -8.5x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MRNA *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 10.9x | ||
SGEN Seagen | 18.8x | 22.6% | US$43.2b |
BIIB Biogen | 3.5x | 2.2% | US$34.3b |
GILD Gilead Sciences | 3.1x | 2.2% | US$83.5b |
A068270 Celltrion | 18.3x | 19.6% | ₩39.8t |
MRNA * Moderna | 9.9x | 20.0% | Mex$49.5b |
Price-To-Sales vs Peers: MRNA * is good value based on its Price-To-Sales Ratio (9.9x) compared to the peer average (10.9x).
Price to Earnings Ratio vs Industry
How does MRNA *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: MRNA * is good value based on its Price-To-Sales Ratio (9.9x) compared to the Global Biotechs industry average (10.3x).
Price to Sales Ratio vs Fair Ratio
What is MRNA *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 9.9x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate MRNA *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$2,150.00 | Mex$2,328.69 +8.3% | 40.6% | Mex$5,211.75 | Mex$1,008.73 | n/a | 23 |
May ’25 | Mex$1,906.00 | Mex$2,301.24 +20.7% | 43.7% | Mex$5,311.88 | Mex$1,010.97 | n/a | 22 |
Apr ’25 | Mex$1,786.95 | Mex$2,229.51 +24.8% | 42.8% | Mex$5,153.50 | Mex$980.83 | n/a | 23 |
Mar ’25 | Mex$1,587.62 | Mex$2,269.43 +42.9% | 42.4% | Mex$5,275.77 | Mex$1,021.12 | n/a | 24 |
Feb ’25 | Mex$1,672.00 | Mex$2,295.56 +37.3% | 45.8% | Mex$5,316.75 | Mex$1,029.05 | n/a | 22 |
Jan ’25 | Mex$1,665.00 | Mex$2,335.47 +40.3% | 46.7% | Mex$5,150.37 | Mex$892.73 | n/a | 22 |
Dec ’24 | Mex$1,365.03 | Mex$2,403.52 +76.1% | 44.9% | Mex$5,159.10 | Mex$894.24 | n/a | 22 |
Nov ’24 | Mex$1,365.00 | Mex$3,097.30 +126.9% | 45.0% | Mex$7,763.01 | Mex$1,155.42 | n/a | 21 |
Oct ’24 | Mex$1,796.55 | Mex$3,122.25 +73.8% | 42.5% | Mex$7,360.96 | Mex$1,129.82 | n/a | 20 |
Sep ’24 | Mex$1,927.00 | Mex$3,068.94 +59.3% | 42.4% | Mex$7,231.31 | Mex$1,143.56 | n/a | 20 |
Aug ’24 | Mex$1,920.00 | Mex$3,363.33 +75.2% | 38.9% | Mex$7,236.34 | Mex$1,379.95 | n/a | 19 |
Jul ’24 | Mex$2,100.00 | Mex$3,662.21 +74.4% | 34.7% | Mex$7,366.16 | Mex$1,404.71 | n/a | 17 |
Jun ’24 | Mex$2,263.24 | Mex$3,735.78 +65.1% | 34.4% | Mex$7,578.71 | Mex$1,639.12 | n/a | 18 |
May ’24 | Mex$2,388.00 | Mex$3,945.24 +65.2% | 33.1% | Mex$7,750.54 | Mex$1,676.28 | Mex$1,906.00 | 17 |
Apr ’24 | Mex$2,771.00 | Mex$4,214.26 +52.1% | 39.0% | Mex$9,608.03 | Mex$1,765.90 | Mex$1,786.95 | 17 |
Mar ’24 | Mex$2,436.00 | Mex$3,996.48 +64.1% | 39.5% | Mex$9,160.07 | Mex$1,683.57 | Mex$1,587.62 | 17 |
Feb ’24 | Mex$3,248.00 | Mex$4,299.40 +32.4% | 38.7% | Mex$9,492.21 | Mex$2,082.28 | Mex$1,672.00 | 16 |
Jan ’24 | Mex$3,475.87 | Mex$4,407.23 +26.8% | 41.2% | Mex$10,003.06 | Mex$2,016.43 | Mex$1,665.00 | 16 |
Dec ’23 | Mex$3,450.00 | Mex$4,101.99 +18.9% | 43.4% | Mex$9,825.36 | Mex$1,961.19 | Mex$1,365.03 | 16 |
Nov ’23 | Mex$3,049.99 | Mex$4,145.42 +35.9% | 45.1% | Mex$10,084.53 | Mex$2,012.92 | Mex$1,365.00 | 16 |
Oct ’23 | Mex$2,421.99 | Mex$4,388.16 +81.2% | 42.8% | Mex$10,182.24 | Mex$1,489.10 | Mex$1,796.55 | 15 |
Sep ’23 | Mex$2,796.36 | Mex$4,354.00 +55.7% | 43.0% | Mex$10,294.97 | Mex$1,505.59 | Mex$1,927.00 | 16 |
Aug ’23 | Mex$3,355.50 | Mex$4,357.10 +29.8% | 43.0% | Mex$10,314.35 | Mex$1,569.58 | Mex$1,920.00 | 16 |
Jul ’23 | Mex$3,025.00 | Mex$4,150.76 +37.2% | 44.0% | Mex$9,904.09 | Mex$1,370.13 | Mex$2,100.00 | 16 |
Jun ’23 | Mex$2,825.00 | Mex$4,229.72 +49.7% | 43.5% | Mex$10,062.82 | Mex$1,590.96 | Mex$2,263.24 | 16 |
May ’23 | Mex$2,758.00 | Mex$4,599.85 +66.8% | 42.2% | Mex$10,027.35 | Mex$1,585.35 | Mex$2,388.00 | 17 |
Analyst Forecast: Target price is less than 20% higher than the current share price.